Citation Impact
Citing Papers
Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer
2009
Spectrum of Phosphatidylinositol 3-Kinase Pathway Gene Alterations in Bladder Cancer
2009
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
2012
Pten Deficiency in Melanocytes Results in Resistance to Hair Graying and Susceptibility to Carcinogen-Induced Melanomagenesis
2008 StandoutNobel
HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF -Mutant Colorectal Cancer by Downregulation of c-FLIPL
2015
Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies
2014
Similar Nucleotide Excision Repair Capacity in Melanocytes and Melanoma Cells
2010 StandoutNobel
Recurrent BRAF mutations in Langerhans cell histiocytosis
2010 Standout
Colorectal cancer statistics, 2020
2020 Standout
Infrared molecular fingerprinting of blood-based liquid biopsies for the detection of cancer
2021 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Skin cancer in solid organ transplant recipients: Advances in therapy and management
2011
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
2014 Standout
Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis
2016
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
2014 Standout
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis
2016
Myasthenia Gravis
2016 Standout
A view on drug resistance in cancer
2019 StandoutNature
Microsatellite Instability in Colorectal Cancer
2010 Standout
Frequent p16-Independent Inactivation of p14ARF in Human Melanoma
2008
The biology and management of non-small cell lung cancer
2018 StandoutNature
Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
2014 StandoutNature
Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
2014
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Crohn's disease
2012 Standout
The mini-driver model of polygenic cancer evolution
2015 StandoutNobel
Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
2015
Comparison of KRAS mutation analysis of primary tumors and matched circulating cell-free DNA in plasmas of patients with colorectal cancer
2014
SOX2 modulates alternative splicing in transitional cell carcinoma
2010
Colorectal cancer
2013 Standout
Current and future perspectives of liquid biopsies in genomics-driven oncology
2018 Standout
Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer
2011
Mechanisms of, and Barriers to, Horizontal Gene Transfer between Bacteria
2005
Lung cancer: current therapies and new targeted treatments
2016 Standout
Deep learning for prediction of colorectal cancer outcome: a discovery and validation study
2020
Colorectal cancer
2019 Standout
Fibroblast growth factor signalling: from development to cancer
2010 Standout
Cell-free nucleic acids as biomarkers in cancer patients
2011 Standout
Skin cancer in solid organ transplant recipients: Advances in therapy and management
2011
Crohn's disease
2016 Standout
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
2014
BRAF inhibition improves tumor recognition by the immune system
2012
MicroRNA biogenesis pathways in cancer
2015 Standout
Deep learning in histopathology: the path to the clinic
2021 Standout
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
2012 Nature
Prognostic Value ofBRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer
2016
The essence of senescence: Figure 1.
2010 Standout
Expansion of the eukaryotic proteome by alternative splicing
2010 StandoutNature
Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma
2017
Liquid biopsies come of age: towards implementation of circulating tumour DNA
2017 Standout
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
2015
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis
2015
BRAFE600 in benign and malignant human tumours
2007
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
2017 Standout
Ulcerative colitis
2016 Standout
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Metabolomics reveals novel blood plasma biomarkers associated to the BRCA1-mutated phenotype of human breast cancer
2017
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
2013
Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression
2010
Call of the wild: antibiotic resistance genes in natural environments
2010 Standout
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
2013 Standout
Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
2017 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
The Impact of Dietary Fiber on Gut Microbiota in Host Health and Disease
2018 Standout
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
2012
Tumour-microenvironmental interactions: paths to progression and targets for treatment
2010
Hypomethylation of a LINE-1 Promoter Activates an Alternate Transcript of the MET Oncogene in Bladders with Cancer
2010
Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner
2009
Biofortification of crops with seven mineral elements often lacking in human diets – iron, zinc, copper, calcium, magnesium, selenium and iodine
2009 Standout
Tumour heterogeneity and resistance to cancer therapies
2017 Standout
Malignant melanoma: genetics and therapeutics in the genomic era
2006
Animal nutrition with feeds from genetically modified plants
2005
Alternative splicing and RNA selection pressure — evolutionary consequences for eukaryotic genomes
2006
Molecular biology and targeted therapies for urothelial carcinoma
2015
Biomarker-driven and molecular targeted therapies for colorectal cancers
2017
Mobile Genetic Elements Associated with Antimicrobial Resistance
2018 Standout
Molecular Testing in Colorectal Cancer
2012
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Long Noncoding RNA and Cancer: A New Paradigm
2017 Standout
NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology
2011
Immunotherapy for Colorectal Cancer
2017
BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
2014
Clinical Significance and Prognostic Relevance of Microsatellite Instability in Sporadic Colorectal Cancer Patients
2017
Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population‐based IBDSL cohort
2016
Non-V600BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer
2017
Comparison of KRAS Mutation Assessment in Tumor DNA and Circulating Free DNA in Plasma and Serum Samples
2012
Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis
2007
Colorectal cancer statistics, 2017
2017 Standout
Changes in mutational status during third‐line treatment for metastatic colorectal cancer—Results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma
2014
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America
2016 Standout
Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer
2016
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
2011
Resistance to Anti-EGFR Therapy in Colorectal Cancer: From Heterogeneity to Convergent Evolution
2014
Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis
2007
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
2015
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
2017 StandoutNobel
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
Analysis of nanoparticle delivery to tumours
2016 Standout
Promotion of direct reprogramming by transformation-deficient Myc
2010 StandoutNobel
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer
2009
Cancers Complicating Inflammatory Bowel Disease
2015
Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
2011
Antimicrobial Resistance in ESKAPE Pathogens
2020 Standout
Genomic Landscape of Appendiceal Neoplasms
2018
Works of Philip Chambers being referenced
Value of Mismatch Repair, KRAS , and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer
2011
2015
PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients
2008
Fate of genetically modified maize DNA in the oral cavity and rumen of sheep
2003
Expression of hTERT immortalises normal human urothelial cells without inactivation of the p16/Rb pathway
2006
AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K
2009
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck
2009
Survival of free DNA encoding antibiotic resistance from transgenic maize and the transformation activity of DNA in ovine saliva, ovine rumen fluid and silage effluent
2000
A mutation hotspot at the p14ARF splice site
2005
Integrated genomic and transcriptional analysis of the in vitro evolution of telomerase‐immortalized urothelial cells (TERT‐NHUC)
2009
Levels of DNA Methylation Vary at CpG Sites across the BRCA1 Promoter, and Differ According to Triple Negative and “BRCA-Like” Status, in Both Blood and Tumour DNA
2016
Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.
2011
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
2009
No Evidence for BRAF as a Melanoma/Nevus Susceptibility Gene
2005
Intra-tumoral Heterogeneity ofKRASandBRAFMutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
2011